【摘要】 目的:观察吉非替尼(Gefitinib,ZD1839)治疗非小细胞肺癌的疗效及毒副作用。方法:自2005年2月-2006年2月用吉非替尼250mg,每日口服,治疗失去手术机会及放化疗无效的非小细胞肺癌患者32例。结果:32例患者均可评价,获得CR2例(6.25%),PR5例(15.63%),有效患者共7例(21.88%);SD15例(46.88%),其中持续时间≥24周者14例;故临床获益率为65.63%[(2+5+14)/32];PD10例(31.25%)。与药物相关的不良反应依次为:皮疹15例(46.88%),恶心8例(25%),腹泻7例(21.88%),皮肤干燥4例(12.5%),乏力2例(6.25%),其它如发热、口腔溃疡及关节痛等副反应发生率均<5%。实验室指标未发现异常。结论:吉非替尼治疗晚期非小细胞肺癌有效,毒副反应少,患者耐受性好,值得推广应用。更多还原

【Abstract】 Objective:To Observe the efficacy and toxic and side effect of Gerfitinib(ZD1839) in treatinent of non-small cell lung cancer. Methods: From Feb.2005 to Feb.2006,oral Gefitinib in dose of 250mg daily were given in 32 patients with advanced non-small cell lung cancer.Results: 2 of 32 patients(6.25%)had complete response(CR),5(15.63%) Partial response(PR).7 of 32 patients(21.88%) was effective to the medicine.The condition in 15 patients wasstable including 14 ones with stable duration more than or equal to 24 Weeks.So the effective rate was 65.63%.10 Patients had progressive diseases.The adverse reaction induced by medication was skin rash in 15 patients,nausea in 8 ones,diarrhea in 7 ones,Xerosis cutis in 4 ones and fatigue in 2 ones.Other adverse reaction included fever,dental ulcer and athralgia(<5%),There was no abnormal laboratory index.Conclusion: Gefitinib is effective in treatment of advanced non-small cell lung cancer,with less toxi C and side effect and better tolerance.The medication should be recommeded.更多还原